AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 221 min read$UTHR

ROTHBLATT MARTINE A sold $5.3M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $560.07 ($552.52–$566.43, $5.32M total) across 14 trades on 2026-10-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 22, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale adds new information about insider sentiment and may influence short‑term trading dynamics.

02

Market read

First‑report insider sale of $5.3M; modest but material for traders monitoring insider activity.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, which may mitigate negative signaling.

Relevance 5/10Novelty 5/10Timing: after-hours on 2026‑10‑21

Background

SEC Form 4 filing discloses an insider transaction by United Therapeutics' chairperson and CEO.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $5.3M of United Therapeutics shares via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

likely downward pressure as the market absorbs the large insider sell.

Evidence & confidence

A C‑suite insider disposing of multi‑million‑dollar equity often signals reduced confidence, prompting traders to anticipate a modest price dip.

Market effects

Sector

Minimal impact on the biotech/biopharma sector; the sale is company‑specific.

Regional

Limited to U.S. markets where UTHR trades.

Global

Low; no broader macro or sector ripple.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to fundamentals, so the stock may remain stable.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company listed on NASDAQ under ticker UTHR.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics, insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min